Optimizing Treatment Strategies for Adult Attention-Deficit Hyperactivity Disorder (ADHD) (R01 Clinical Trial Required)
Grant Opportunity Analysis
The National Institutes of Health (NIH) has announced a funding opportunity titled "Optimizing Treatment Strategies for Adult Attention-Deficit Hyperactivity Disorder (ADHD) (R01 Clinical Trial Required)" aimed at advancing clinical research on non-stimulant treatment options for adults diagnosed with ADHD. This initiative seeks applications for clinical trials that explore non-stimulant medications, psychosocial interventions, and device-based treatments, particularly in cases where stimulant therapies are ineffective, intolerable, or undesirable. The research is expected to take place in community practice settings to enhance scalability and utility, with a focus on participants aged 18 and older who meet DSM-5-TR criteria for ADHD, including those with comorbid conditions. A total funding amount of $3,000,000 is available for up to four awards, with a maximum project duration of five years. Interested applicants must comply with NIH data management policies and submit their proposals by November 25, 2025; for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov.
Eligible Applicants
Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.